NFC-1

Small molecule

AAevi Genomic Medicine, LLC, a Cerecor company

NFC-1 is one of 9 small molecule programs targeting Genetic Disorder. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Genetic DisorderActive, not recruiting

Genetic DisorderPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Genetic Disorder

#DrugCompanyPhaseTrials

Busulfex

Cellcept

1 3

Fludara

Sanofi

Phase 2

1 4

Atgam

Novartis

Phase 2

1 5

Neoral

Novartis

Phase 2

1 6

Medrol

Pfizer

Phase 2

1 7

Imcivree

Rhythm Pharmaceuticals

Phase 2

1 8

Alkeran

AApotex Inc.

Phase 2

1 9

NFC-1

AAevi Genomic Medicine, LLC, a Cerecor company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Single Dose1 trial

Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder

Completed·AAevi Genomic Medicine, LLC, a Cerecor company·Phase 1·NCT02286817·30 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

Completed·AAevi Genomic Medicine, LLC, a Cerecor company·Phase 1·NCT02895906·2 enrolled

Genetic Disorder1 trial

Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

Completed·AAevi Genomic Medicine, LLC, a Cerecor company·Phase 2/3·NCT02777931·101 enrolled

ADHD1 trial

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Completed·AAevi Genomic Medicine, LLC, a Cerecor company·Phase 1·NCT03006367·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for NFC-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NFC-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NFC-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aevi Genomic Medicine, LLC, a Cerecor company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAevi Genomic Medicine, LLC, a Cerecor company

NFC-1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Single Dose1 trial

Safety and Efficacy1 trial

Genetic Disorder1 trial

ADHD1 trial

References

Drug Info

Quick Facts

Related News